These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis patients in the UK. Moore A; Phillips C; Hunsche E; Pellissier J; Crespi S Pharmacoeconomics; 2004; 22(10):643-60. PubMed ID: 15244490 [TBL] [Abstract][Full Text] [Related]
3. The hidden costs of arthritis treatment and the cost of new therapy--the burden of non-steroidal anti-inflammatory drug gastropathy. Moore RA Rheumatology (Oxford); 2002 Apr; 41 Supp 1():7-15; discussion 35-42. PubMed ID: 12173280 [TBL] [Abstract][Full Text] [Related]
5. Economic evaluation of celecoxib, a new cyclo-oxygenase 2 specific inhibitor, in Switzerland. Chancellor JV; Hunsche E; de Cruz E; Sarasin FP Pharmacoeconomics; 2001; 19 Suppl 1():59-75. PubMed ID: 11280106 [TBL] [Abstract][Full Text] [Related]
6. Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed celecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data. Layton D; Hughes K; Harris S; Shakir SA Rheumatology (Oxford); 2003 Nov; 42(11):1332-41. PubMed ID: 12810929 [TBL] [Abstract][Full Text] [Related]
7. Gastrointestinal and cardiovascular risk of non-selective NSAIDs and COX-2 inhibitors in elderly patients with knee osteoarthritis. Turajane T; Wongbunnak R; Patcharatrakul T; Ratansumawong K; Poigampetch Y; Songpatanasilp T J Med Assoc Thai; 2009 Dec; 92 Suppl 6():S19-26. PubMed ID: 20128070 [TBL] [Abstract][Full Text] [Related]
8. Cost of prescribed NSAID-related gastrointestinal adverse events in elderly patients. Rahme E; Joseph L; Kong SX; Watson DJ; LeLorier J Br J Clin Pharmacol; 2001 Aug; 52(2):185-92. PubMed ID: 11488776 [TBL] [Abstract][Full Text] [Related]
9. Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events. Scheiman JM; Hindley CE Clin Ther; 2010 Apr; 32(4):667-77. PubMed ID: 20435236 [TBL] [Abstract][Full Text] [Related]
10. Results from a patient survey to assess gastrointestinal burden of non-steroidal anti-inflammatory drug therapy contrasted with a review of data from EVA to determine satisfaction with rofecoxib. Steinfeld S; Bjørke PA Rheumatology (Oxford); 2002 Apr; 41 Supp 1():23-7; discussion 35-42. PubMed ID: 12173277 [TBL] [Abstract][Full Text] [Related]
11. An epidemiological approach to assess the economic burden of NSAID-induced gastrointestinal events in The Netherlands. Herings RM; Klungel OH Pharmacoeconomics; 2001; 19(6):655-65. PubMed ID: 11456213 [TBL] [Abstract][Full Text] [Related]
12. [Recommendation for the prevention and treatment of non-steroidal anti-inflammatory drug-induced gastrointestinal ulcers and its complications]. ; Zhonghua Nei Ke Za Zhi; 2017 Jan; 56(1):81-85. PubMed ID: 28056333 [TBL] [Abstract][Full Text] [Related]
13. Clinical and economic implications of upper gastrointestinal adverse events in Asian rheumatological patients on long-term non-steroidal anti-inflammatory drugs. Pok LSL; Shabaruddin FH; Dahlui M; Sockalingam S; Mohamed Said MS; Rosman A; Lau IS; Isa LM; Hussein H; Ng CT; Mahadeva S Int J Rheum Dis; 2018 May; 21(5):943-951. PubMed ID: 29314744 [TBL] [Abstract][Full Text] [Related]
14. NSAID alternatives. Med Lett Drugs Ther; 2005 Jan; 47(1200):8. PubMed ID: 15647706 [TBL] [Abstract][Full Text] [Related]
15. Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed rofecoxib and meloxicam in general practice in England using prescription-event monitoring data. Layton D; Heeley E; Hughes K; Shakir SA Rheumatology (Oxford); 2003 May; 42(5):622-31. PubMed ID: 12709537 [TBL] [Abstract][Full Text] [Related]
16. Rofecoxib (Vioxx)--the first of a new generation of NSAIDs. MacConnachie AM Intensive Crit Care Nurs; 2000 Jun; 16(3):201-2. PubMed ID: 10859630 [TBL] [Abstract][Full Text] [Related]
17. Health care resource utilization and costs of NSAID-induced gastrointestinal toxicity. A population-based study in Switzerland. Delcò F; Michetti P; Beglinger C; Fried M; Szucs TD Digestion; 2004; 69(1):10-9. PubMed ID: 14755148 [TBL] [Abstract][Full Text] [Related]
18. The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review. Hooper L; Brown TJ; Elliott R; Payne K; Roberts C; Symmons D BMJ; 2004 Oct; 329(7472):948. PubMed ID: 15475342 [TBL] [Abstract][Full Text] [Related]
19. The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis. Maetzel A; Krahn M; Naglie G Arthritis Rheum; 2003 Jun; 49(3):283-92. PubMed ID: 12794781 [TBL] [Abstract][Full Text] [Related]
20. The risks and costs of upper gastrointestinal disease attributable to NSAIDs. Smalley WE; Griffin MR Gastroenterol Clin North Am; 1996 Jun; 25(2):373-96. PubMed ID: 9229579 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]